CNTA
Income statement / Annual
Last year (2024), Centessa Pharmaceuticals plc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Centessa Pharmaceuticals plc's net income was -$235.76 M.
See Centessa Pharmaceuticals plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$6.85 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$130,919.00
|
$33,995.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$6.85 M
|
-$130,919.00
|
-$33,995.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$150.24 M
|
$124.41 M
|
$155.08 M
|
$96.31 M
|
$9.30 M
|
$4.26 M
|
| General & Administrative Expenses |
$50.81 M
|
$53.73 M
|
$55.20 M
|
$43.01 M
|
$1.14 M
|
$790,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$42.93 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$50.81 M
|
$53.73 M
|
$55.20 M
|
$42.97 M
|
$1.14 M
|
$790,000.00
|
| Other Expenses |
$0.00
|
$0.00
|
$2.34 M
|
$0.00
|
$155,000.00
|
$105,000.00
|
| Operating Expenses |
$201.06 M
|
$178.14 M
|
$210.28 M
|
$139.28 M
|
$10.44 M
|
$5.05 M
|
| Cost And Expenses |
$0.00
|
$178.14 M
|
$210.28 M
|
$139.31 M
|
$10.44 M
|
$5.05 M
|
| Interest Income |
$14.02 M
|
$10.48 M
|
$7,033.00
|
$2,549.00
|
$378.00
|
$5,000.00
|
| Interest Expense |
-$10.08 M
|
$9.91 M
|
$7.03 M
|
$2.55 M
|
$378,000.00
|
$118,000.00
|
| Depreciation & Amortization |
$942,396.00
|
$813,139.00
|
$130,919.00
|
$33,995.00
|
$6,000.00
|
$6,000.00
|
| EBITDA |
-$221.97 M |
-$166.07 M |
-$212.26 M |
-$379.16 M |
-$10.43 M |
-$4.94 M |
| EBITDA Ratio |
0
|
-24.23
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-24.99
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$31.96 M
|
-$4.86 M
|
-$4.69 M
|
-$6.87 M
|
-$223,000.00
|
-$8,000.00
|
| Income Before Tax |
-$233.01 M
|
-$176.14 M
|
-$216.95 M
|
-$381.74 M
|
-$10.66 M
|
-$5.06 M
|
| Income Before Tax Ratio |
0
|
-25.7
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$2.84 M
|
-$25.06 M
|
-$747,000.00
|
$113,986.00
|
$378,000.00
|
$223,000.00
|
| Net Income |
-$235.76 M
|
-$151.09 M
|
-$216.21 M
|
-$381.85 M
|
-$11.04 M
|
-$5.28 M
|
| Net Income Ratio |
0
|
-22.05
|
0
|
0
|
0
|
0
|
| EPS |
-2.06 |
-1.57 |
-2.31 |
-4.24 |
-0.0777 |
-0.0745 |
| EPS Diluted |
-2.06 |
-1.57 |
-2.31 |
-4.24 |
-0.0777 |
-0.0745 |
| Weighted Average Shares Out |
$114.47 M
|
$96.18 M
|
$93.40 M
|
$89.99 M
|
$142.06 M
|
$70.89 M
|
| Weighted Average Shares Out Diluted |
$114.47 M
|
$96.18 M
|
$93.40 M
|
$89.99 M
|
$142.06 M
|
$70.89 M
|
| Link |
|
|
|
|
|
|
